董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Juan Jose Chacon Quiros | 男 | Chief Executive Officer and Director | 46 | 32.35万美元 | 未持股 | 2018-06-30 |
| Ed Schutter | 男 | Director | 67 | 未披露 | 未持股 | 2018-06-30 |
| Allan Weinstein | 男 | Director | 69 | 未披露 | 未持股 | 2018-06-30 |
| David Hung | 男 | Director | 61 | 未披露 | 未持股 | 2018-06-30 |
| Nicholas Lewin | 男 | Director | 41 | 未披露 | 未持股 | 2018-06-30 |
| Dennis Condon | 男 | Director | 69 | 3.68万美元 | 未持股 | 2018-06-30 |
| David Hung | 男 | Director | 61 | 未披露 | 未持股 | 2018-06-30 |
| Lisa N. Colleran | 女 | Director | 60 | 未披露 | 未持股 | 2018-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Juan Jose Chacon Quiros | 男 | Chief Executive Officer and Director | 46 | 32.35万美元 | 未持股 | 2018-06-30 |
| Salvador Dada Santos | 男 | Chief Operating Officer | 36 | 23.42万美元 | 未持股 | 2018-06-30 |
| Roberto De Mezerville | 男 | Chief Technology Officer | 38 | 未披露 | 未持股 | 2018-06-30 |
| Jeremy Livianu | 男 | General Counsel | 37 | 未披露 | 未持股 | 2018-06-30 |
| Alberto Quesada | 男 | Vice President, Quality & OUS Regulatory Affairs | 52 | 未披露 | 未持股 | 2018-06-30 |
| Eddie De Oliveira | 男 | Vice President of Sales, Brazil | 36 | 未披露 | 未持股 | 2018-06-30 |
| Renee Gaeta | 女 | Chief Financial Officer | 37 | 未披露 | 未持股 | 2018-06-30 |
董事简历
中英对照 | 中文 | 英文- Juan Jose Chacon Quiros
-
Juan Jose Chacon Quiros于2004年创立了Establishment Labs，S.A.，并自2013年成立以来一直担任Establishment Labs HoldingsInc.的董事兼首席执行官。Chacon Quiros先生一直参与美学行业的几个部门，包括担任拉丁美洲美容医疗器械分销业务的总经理近十年，在此之前，担任哥斯达黎加整形和重建外科诊所的业务开发经理。他也曾担任the Rugby Federation of Costa的总裁（从2009年到2015年）。Chac&243；n Quir&243；s先生在普瓦捷经济学院（Academie de Poitiers Economics）获得学士学位，并在马萨诸塞州阿默斯特大学（University of Massachusetts at Amherst）就读。他持有the MIT Sloan Advanced Certificate for Executives（ACE）的管理、创新和技术。
Juan Jose Chacon Quiros founded Establishment Labs, S.A. in 2004 and has been a director and the Chief Executive Officer of Establishment Labs Holdings Inc. since its inception in 2013. Mr. Chacon Quiros has been involved in several sectors of the aesthetics industry, including serving for almost a decade as General Manager of an aesthetic medical device distribution business in Latin America, and prior to that as Business Development Manager of a plastic and reconstructive surgery clinic in Costa Rica. He also served as President of the Rugby Federation of Costa Rica from 2009 to 2015. Mr. Chacón Quirós received his Baccalaureate at the Academie de Poitiers Economics and attended the University of Massachusetts at Amherst. He holds the MIT Sloan Advanced Certificate for Executives (ACE) in Management, Innovation and Technology. - Juan Jose Chacon Quiros于2004年创立了Establishment Labs，S.A.，并自2013年成立以来一直担任Establishment Labs HoldingsInc.的董事兼首席执行官。Chacon Quiros先生一直参与美学行业的几个部门，包括担任拉丁美洲美容医疗器械分销业务的总经理近十年，在此之前，担任哥斯达黎加整形和重建外科诊所的业务开发经理。他也曾担任the Rugby Federation of Costa的总裁（从2009年到2015年）。Chac&243；n Quir&243；s先生在普瓦捷经济学院（Academie de Poitiers Economics）获得学士学位，并在马萨诸塞州阿默斯特大学（University of Massachusetts at Amherst）就读。他持有the MIT Sloan Advanced Certificate for Executives（ACE）的管理、创新和技术。
- Juan Jose Chacon Quiros founded Establishment Labs, S.A. in 2004 and has been a director and the Chief Executive Officer of Establishment Labs Holdings Inc. since its inception in 2013. Mr. Chacon Quiros has been involved in several sectors of the aesthetics industry, including serving for almost a decade as General Manager of an aesthetic medical device distribution business in Latin America, and prior to that as Business Development Manager of a plastic and reconstructive surgery clinic in Costa Rica. He also served as President of the Rugby Federation of Costa Rica from 2009 to 2015. Mr. Chacón Quirós received his Baccalaureate at the Academie de Poitiers Economics and attended the University of Massachusetts at Amherst. He holds the MIT Sloan Advanced Certificate for Executives (ACE) in Management, Innovation and Technology.
- Ed Schutter
-
Ed Schutter自2016年1月以来一直担任我们的董事会成员。他拥有超过三十年的制药行业经验，自2010年4月起担任Arbor Pharmaceuticals，Inc.的总裁兼首席执行官。在加入Arbor Pharmaceuticals之前，Schutter先生曾在Sciele Pharma，Inc.担任多个职位，该公司是Shionogi&Co.，Ltd.的子公司，包括2007年至2009年担任总裁兼首席运营官，以及巴塞尔Solvay S.A.全球业务发展Vice President，瑞士从2002年到2006年。他也曾担任Solvay公司的美国子公司的商业运营高级管理职务（任职公司20年）。Schutter先生在Reid-Provident Laboratories股份有限公司（Reid-Provident Laboratories，Inc.）开始了他的制药职业生涯，该公司是一家位于乔治亚州亚特兰大的小型创业制药公司。他目前任职于Knight Therapeutics，Inc.、Vensun Pharmaceuticals，Inc.（私人控股公司）、Mercer University和Georgia Bio（私人控股公司）的董事会。Schutter先生拥有Mercer University的药物科学学位和Kennesaw State University的工商管理硕士学位。
Ed Schutter has served on our board of directors since January 2016. He has over thirty years of pharmaceutical industry experience and has served as the President and Chief Executive Officer of Arbor Pharmaceuticals, Inc. since April 2010. Prior to joining Arbor Pharmaceuticals, Mr. Schutter served in various roles at Sciele Pharma, Inc., a subsidiary of Shionogi & Co., Ltd., including as President and Chief Operating Officer from 2007 to 2009 and as Vice President of Global Business Development at Solvay S.A. in Basel, Switzerland from 2002 to 2006. He also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. Mr. Schutter began his pharmaceutical career with Reid-Provident Laboratories, Inc., a small entrepreneurial pharmaceutical company based in Atlanta, Georgia. He currently serves on the board of Knight Therapeutics, Inc., Vensun Pharmaceuticals, Inc., a privately held company, Mercer University and Georgia Bio, a privately held company. Mr. Schutter has a degree in Pharmaceutical Sciences from Mercer University and an M.B.A. from Kennesaw State University. - Ed Schutter自2016年1月以来一直担任我们的董事会成员。他拥有超过三十年的制药行业经验，自2010年4月起担任Arbor Pharmaceuticals，Inc.的总裁兼首席执行官。在加入Arbor Pharmaceuticals之前，Schutter先生曾在Sciele Pharma，Inc.担任多个职位，该公司是Shionogi&Co.，Ltd.的子公司，包括2007年至2009年担任总裁兼首席运营官，以及巴塞尔Solvay S.A.全球业务发展Vice President，瑞士从2002年到2006年。他也曾担任Solvay公司的美国子公司的商业运营高级管理职务（任职公司20年）。Schutter先生在Reid-Provident Laboratories股份有限公司（Reid-Provident Laboratories，Inc.）开始了他的制药职业生涯，该公司是一家位于乔治亚州亚特兰大的小型创业制药公司。他目前任职于Knight Therapeutics，Inc.、Vensun Pharmaceuticals，Inc.（私人控股公司）、Mercer University和Georgia Bio（私人控股公司）的董事会。Schutter先生拥有Mercer University的药物科学学位和Kennesaw State University的工商管理硕士学位。
- Ed Schutter has served on our board of directors since January 2016. He has over thirty years of pharmaceutical industry experience and has served as the President and Chief Executive Officer of Arbor Pharmaceuticals, Inc. since April 2010. Prior to joining Arbor Pharmaceuticals, Mr. Schutter served in various roles at Sciele Pharma, Inc., a subsidiary of Shionogi & Co., Ltd., including as President and Chief Operating Officer from 2007 to 2009 and as Vice President of Global Business Development at Solvay S.A. in Basel, Switzerland from 2002 to 2006. He also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. Mr. Schutter began his pharmaceutical career with Reid-Provident Laboratories, Inc., a small entrepreneurial pharmaceutical company based in Atlanta, Georgia. He currently serves on the board of Knight Therapeutics, Inc., Vensun Pharmaceuticals, Inc., a privately held company, Mercer University and Georgia Bio, a privately held company. Mr. Schutter has a degree in Pharmaceutical Sciences from Mercer University and an M.B.A. from Kennesaw State University.
- Allan Weinstein
-
Allan Weinstein自2016年1月以来一直担任我们的董事会成员。他是一名独立企业家，专注于生命科学和医疗器械行业的知识产权。目前，他积极任职于以下公司:Spiritus Pharmaceuticals公司（专业制药公司，致力于改善呼吸系统疾病患者的生活）的主席（2012年至2017年），MinibarRX，LLC的主席（直到被收购），一家私人持有的物联网平台公司，用于管理疫苗和生物制品，其首要使命是通过提高接种率来预防疾病；Sharestream的董事长，从2003年开始担任全球领先的在线视频平台和媒体管理解决方案提供商；InstantDX/OnCallData的董事长，从2000年开始，他是电子处方和梦百合交易服务的先驱；从2008年开始，他是即时医疗诊断公司（Instant Medical Diagnostics）的董事长，该公司是一家一步到位的快速诊断平台；他还是拥有25年历史的私营知识产权制药公司J-Med Pharmaceuticals，Inc.的联合创始人，拥有多元化的专利组合，该专利组合始于处方药和非处方药的日间/夜间抗组胺/减充血剂产品的许可，用于感冒，咳嗽和流感。在过去，Weinstein博士担任学术职能包括担任乔治敦大学（Georgetown University）的医学助理临床教授和马里兰州贝塞斯达（Bethesda）的美国国立卫生研究院（National Institutes of Health）的顾问，同时在华盛顿行医，D.C.他在Lafayette College获得生物学学士学位，在University of Kentucky获得医学博士学位。Weinstein博士是McGraw-Hill和Random House出版的《哮喘:患者及其家人哮喘和过敏自我管理的完整指南》一书的作者。他获得内科和过敏和临床免疫学的董事会认证，并完成了丹佛National Jewish Health的医学培训奖学金。
Allan Weinstein has served on our board of directors since January 2016. He is an independent entrepreneur focused on intellectual property in the life sciences and medical device industries. Currently, he is actively associated with the following companies: Chairman of Spiritus Pharmaceuticals, from 2012 a specialty pharmaceutical company devoted to improving the lives of those with respiratory diseases; Chairman of MinibarRx, LLC, from 2012 to 2017 until its acquisition, a privately held IoT platform company for managing vaccines and biologics with the foremost mission of disease prevention through increased vaccination rates; Chairman of ShareStream, from 2003 a leading online video platform and media-management solution provider for education worldwide; Chairman of InstantDx/OnCallData, from 2000 a pioneer in electronic prescribing and healthcare-transaction services; Chairman of Instant Medical Diagnostics, from 2008 a one-step rapid-diagnostic platform; and Co-founder of J-Med Pharmaceuticals, Inc., a 25-year-old privately held intellectual property pharmaceutical company, with a diversified patent portfolio that began with the licensing of both prescription and over-the-counter day/night antihistamine/decongestant products for cold, cough, and flu. In the past, Dr. Weinstein has served in academic functions including as an Assistant Clinical Professor of Medicine at Georgetown University and as a Consultant to the National Institutes of Health in Bethesda, Maryland, while practicing medicine in Washington, D.C. He received an A.B. in Biology from Lafayette College and an M.D. from the University of Kentucky. Dr. Weinstein is the author of the book Asthma: The Complete Guide to Self-Management of Asthma and Allergies for Patients and Their Families, published by McGraw-Hill and Random House. He is Board-certified in Internal Medicine and in Allergy and Clinical Immunology, and completed his medical training fellowship at National Jewish Health in Denver. - Allan Weinstein自2016年1月以来一直担任我们的董事会成员。他是一名独立企业家，专注于生命科学和医疗器械行业的知识产权。目前，他积极任职于以下公司:Spiritus Pharmaceuticals公司（专业制药公司，致力于改善呼吸系统疾病患者的生活）的主席（2012年至2017年），MinibarRX，LLC的主席（直到被收购），一家私人持有的物联网平台公司，用于管理疫苗和生物制品，其首要使命是通过提高接种率来预防疾病；Sharestream的董事长，从2003年开始担任全球领先的在线视频平台和媒体管理解决方案提供商；InstantDX/OnCallData的董事长，从2000年开始，他是电子处方和梦百合交易服务的先驱；从2008年开始，他是即时医疗诊断公司（Instant Medical Diagnostics）的董事长，该公司是一家一步到位的快速诊断平台；他还是拥有25年历史的私营知识产权制药公司J-Med Pharmaceuticals，Inc.的联合创始人，拥有多元化的专利组合，该专利组合始于处方药和非处方药的日间/夜间抗组胺/减充血剂产品的许可，用于感冒，咳嗽和流感。在过去，Weinstein博士担任学术职能包括担任乔治敦大学（Georgetown University）的医学助理临床教授和马里兰州贝塞斯达（Bethesda）的美国国立卫生研究院（National Institutes of Health）的顾问，同时在华盛顿行医，D.C.他在Lafayette College获得生物学学士学位，在University of Kentucky获得医学博士学位。Weinstein博士是McGraw-Hill和Random House出版的《哮喘:患者及其家人哮喘和过敏自我管理的完整指南》一书的作者。他获得内科和过敏和临床免疫学的董事会认证，并完成了丹佛National Jewish Health的医学培训奖学金。
- Allan Weinstein has served on our board of directors since January 2016. He is an independent entrepreneur focused on intellectual property in the life sciences and medical device industries. Currently, he is actively associated with the following companies: Chairman of Spiritus Pharmaceuticals, from 2012 a specialty pharmaceutical company devoted to improving the lives of those with respiratory diseases; Chairman of MinibarRx, LLC, from 2012 to 2017 until its acquisition, a privately held IoT platform company for managing vaccines and biologics with the foremost mission of disease prevention through increased vaccination rates; Chairman of ShareStream, from 2003 a leading online video platform and media-management solution provider for education worldwide; Chairman of InstantDx/OnCallData, from 2000 a pioneer in electronic prescribing and healthcare-transaction services; Chairman of Instant Medical Diagnostics, from 2008 a one-step rapid-diagnostic platform; and Co-founder of J-Med Pharmaceuticals, Inc., a 25-year-old privately held intellectual property pharmaceutical company, with a diversified patent portfolio that began with the licensing of both prescription and over-the-counter day/night antihistamine/decongestant products for cold, cough, and flu. In the past, Dr. Weinstein has served in academic functions including as an Assistant Clinical Professor of Medicine at Georgetown University and as a Consultant to the National Institutes of Health in Bethesda, Maryland, while practicing medicine in Washington, D.C. He received an A.B. in Biology from Lafayette College and an M.D. from the University of Kentucky. Dr. Weinstein is the author of the book Asthma: The Complete Guide to Self-Management of Asthma and Allergies for Patients and Their Families, published by McGraw-Hill and Random House. He is Board-certified in Internal Medicine and in Allergy and Clinical Immunology, and completed his medical training fellowship at National Jewish Health in Denver.
- David Hung
-
David Hung是我们的董事会成员。洪博士最近于2017年4月至2018年2月辞职期间担任Axovant Biosciences Inc.的首席执行官。在此之前，洪博士是Medivation，Inc.Medivation的联合创始人之一，并从其子公司Medivation Neurology，Inc.2003年9月成立到2004年12月被Medivation收购担任总裁、首席执行官和董事，Medivation的首席执行官和董事。洪博士曾担任这些职务，直到2016年9月Medivation被Pfizer，Inc.收购。Hung从1998年到2001年担任Pro-Ducture Health，Inc.（一家私人医疗设备公司，专注于乳腺癌细胞学诊断）首席科学官（1998年到1999年）以及总裁、首席执行官和董事（1999年到2001年）。Hung从1996年到1998年担任Chiron Corporation多个高级职位，包括Lead Discovery and Development Vice President和新项目Vice President。洪博士目前担任Establishment Labs HoldingsInc.（纳斯达克市场代码:ESTA）和NovoCure（纳斯达克市场代码:NVCR）的董事，以及Nuvation Bio，Inc.（一家私营生物制药公司）的创始人、总裁兼首席执行官和董事。他此前曾担任Opexa Therapeutics公司（生物制药公司）的董事（从2006年5月到2011年10月）。洪博士在加州大学旧金山分校医学院获得医学博士学位，在哈佛学院获得生物学AB学位。
David Hung serves on our board of directors. Dr. Hung recently served as Chief Executive Officer of Axovant Biosciences Inc. from April 2017 until his resignation in February 2018. Prior to that, Dr. Hung was a co-founder of Medivation, Inc. “Medivation” and served as President, Chief Executive Officer and director of its subsidiary, Medivation Neurology, Inc., from its inception in September 2003 until its acquisition by Medivation in December 2004 at which time he became President, Chief Executive Officer and director of Medivation. Dr. Hung served in those roles until Medivation was acquired by Pfizer, Inc. in September 2016. From 1998 to 2001 Dr. Hung served as Chief Scientific Officer (1998-1999) and as President, Chief Executive Officer and director (1999-2001) of Pro-Duct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. From 1996 to 1998 Dr. Hung served in various senior positions at Chiron Corporation, including as Vice President of Lead Discovery and Development and Vice President of New Projects. Dr. Hung currently serves as a director of Establishment Labs Holdings Inc. (NASDAQ: ESTA) and Novocure (NASDAQ: NVCR), and as founder, President and CEO and director of Nuvation Bio, Inc., a private biopharmaceutical company. He previously served as a director of Opexa Therapeutics, Inc., a biopharmaceutical company, from May 2006 to October 2011. Dr. Hung received an MD from the University of California, San Francisco, School of Medicine, and an AB in Biology from Harvard College. - David Hung是我们的董事会成员。洪博士最近于2017年4月至2018年2月辞职期间担任Axovant Biosciences Inc.的首席执行官。在此之前，洪博士是Medivation，Inc.Medivation的联合创始人之一，并从其子公司Medivation Neurology，Inc.2003年9月成立到2004年12月被Medivation收购担任总裁、首席执行官和董事，Medivation的首席执行官和董事。洪博士曾担任这些职务，直到2016年9月Medivation被Pfizer，Inc.收购。Hung从1998年到2001年担任Pro-Ducture Health，Inc.（一家私人医疗设备公司，专注于乳腺癌细胞学诊断）首席科学官（1998年到1999年）以及总裁、首席执行官和董事（1999年到2001年）。Hung从1996年到1998年担任Chiron Corporation多个高级职位，包括Lead Discovery and Development Vice President和新项目Vice President。洪博士目前担任Establishment Labs HoldingsInc.（纳斯达克市场代码:ESTA）和NovoCure（纳斯达克市场代码:NVCR）的董事，以及Nuvation Bio，Inc.（一家私营生物制药公司）的创始人、总裁兼首席执行官和董事。他此前曾担任Opexa Therapeutics公司（生物制药公司）的董事（从2006年5月到2011年10月）。洪博士在加州大学旧金山分校医学院获得医学博士学位，在哈佛学院获得生物学AB学位。
- David Hung serves on our board of directors. Dr. Hung recently served as Chief Executive Officer of Axovant Biosciences Inc. from April 2017 until his resignation in February 2018. Prior to that, Dr. Hung was a co-founder of Medivation, Inc. “Medivation” and served as President, Chief Executive Officer and director of its subsidiary, Medivation Neurology, Inc., from its inception in September 2003 until its acquisition by Medivation in December 2004 at which time he became President, Chief Executive Officer and director of Medivation. Dr. Hung served in those roles until Medivation was acquired by Pfizer, Inc. in September 2016. From 1998 to 2001 Dr. Hung served as Chief Scientific Officer (1998-1999) and as President, Chief Executive Officer and director (1999-2001) of Pro-Duct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. From 1996 to 1998 Dr. Hung served in various senior positions at Chiron Corporation, including as Vice President of Lead Discovery and Development and Vice President of New Projects. Dr. Hung currently serves as a director of Establishment Labs Holdings Inc. (NASDAQ: ESTA) and Novocure (NASDAQ: NVCR), and as founder, President and CEO and director of Nuvation Bio, Inc., a private biopharmaceutical company. He previously served as a director of Opexa Therapeutics, Inc., a biopharmaceutical company, from May 2006 to October 2011. Dr. Hung received an MD from the University of California, San Francisco, School of Medicine, and an AB in Biology from Harvard College.
- Nicholas Lewin
-
Nicholas Lewin自2015年9月起担任董事会成员，自2017年12月起担任董事长。他自2000年起担任Crown Predator Holdings的管理合伙人，自2000年起担任私人投资者。他曾投资多个行业，以及整个资本结构，特别专注于拥有创新技术和强大知识产权的公司，包括需要与管理层合作的激进情况。他一直担任Halo Maritime Defense Systems公司（私人持有的海事安全产品和解决方案供应商）的董事（2007年以来），以及Dura Medic公司（耐用医疗设备供应商）的董事（2006年以来）。Lewin先生拥有约翰霍普金斯大学（Johns Hopkins University）政治学学士学位。
Nicholas Lewin has served on our board of directors since September 2015 and as Chairman since December 2017. He has been a Managing Partner at Crown Predator Holdings since 2000 and has been a private investor since 2000. He has invested across multiple industries, and throughout the capital structure, with a particular focus on companies with innovative technologies and strong intellectual property, including activist situations that require working with management. He has been a director of Halo Maritime Defense Systems, a privately held provider of maritime security product and solutions, since 2007 and Dura Medic, LLC a durable medical equipment provider, since 2006. Mr. Lewin holds a bachelor’s degree in Political Science from Johns Hopkins University. - Nicholas Lewin自2015年9月起担任董事会成员，自2017年12月起担任董事长。他自2000年起担任Crown Predator Holdings的管理合伙人，自2000年起担任私人投资者。他曾投资多个行业，以及整个资本结构，特别专注于拥有创新技术和强大知识产权的公司，包括需要与管理层合作的激进情况。他一直担任Halo Maritime Defense Systems公司（私人持有的海事安全产品和解决方案供应商）的董事（2007年以来），以及Dura Medic公司（耐用医疗设备供应商）的董事（2006年以来）。Lewin先生拥有约翰霍普金斯大学（Johns Hopkins University）政治学学士学位。
- Nicholas Lewin has served on our board of directors since September 2015 and as Chairman since December 2017. He has been a Managing Partner at Crown Predator Holdings since 2000 and has been a private investor since 2000. He has invested across multiple industries, and throughout the capital structure, with a particular focus on companies with innovative technologies and strong intellectual property, including activist situations that require working with management. He has been a director of Halo Maritime Defense Systems, a privately held provider of maritime security product and solutions, since 2007 and Dura Medic, LLC a durable medical equipment provider, since 2006. Mr. Lewin holds a bachelor’s degree in Political Science from Johns Hopkins University.
- Dennis Condon
-
Dennis Condon自2017年12月以来一直担任我们的董事会成员。2007年7月至2013年1月，他曾担任Merz Aethetics（原名Bioform Medical）的总裁兼首席执行官。Condon从2006年3月到2007年5月担任Aspara Medical总裁和首席执行官，从2005年1月到2006年2月担任Reliant Technology总裁和首席执行官。加入Reliant Technology之前，Condon在整形手术公司Spa Medicus和Mentor Corporation担任多个职位。Condon先生拥有加州大学戴维斯分校（University of California，Davis）生物科学学士学位。
Dennis Condon has served on our board of directors since December 2017. He was President and Chief Executive Officer of Merz Aethetics formerly BioForm Medical from July 2007 to January 2013. From March 2006 to May 2007 Mr. Condon was President and Chief Executive Officer of Aspara Medical, and was President and Chief Executive Officer of Reliant Technology from January 2005 to February 2006. Prior to joining Reliant Technology, Mr. Condon held various roles at Spa Medicus, The Plastic Surgery Company and Mentor Corporation. Mr. Condon holds a bachelor’s degree in Biological Science from University of California, Davis. - Dennis Condon自2017年12月以来一直担任我们的董事会成员。2007年7月至2013年1月，他曾担任Merz Aethetics（原名Bioform Medical）的总裁兼首席执行官。Condon从2006年3月到2007年5月担任Aspara Medical总裁和首席执行官，从2005年1月到2006年2月担任Reliant Technology总裁和首席执行官。加入Reliant Technology之前，Condon在整形手术公司Spa Medicus和Mentor Corporation担任多个职位。Condon先生拥有加州大学戴维斯分校（University of California，Davis）生物科学学士学位。
- Dennis Condon has served on our board of directors since December 2017. He was President and Chief Executive Officer of Merz Aethetics formerly BioForm Medical from July 2007 to January 2013. From March 2006 to May 2007 Mr. Condon was President and Chief Executive Officer of Aspara Medical, and was President and Chief Executive Officer of Reliant Technology from January 2005 to February 2006. Prior to joining Reliant Technology, Mr. Condon held various roles at Spa Medicus, The Plastic Surgery Company and Mentor Corporation. Mr. Condon holds a bachelor’s degree in Biological Science from University of California, Davis.
- David Hung
-
David Hung，担任ARYA Sciences Acquisition Corp.的董事。Hung博士最近担任Axovant Biosciences Inc.的首席执行官(从2017年4月到2018年2月辞职)。2006年5月以来，他担任Acer Therapeutics Inc.董事。2004年12月以来，他担任Medivation, Inc.的总裁、首席执行官和董事。2003年9月Medivation, Inc.的子公司Medivation Neurology, Inc.成立以来，他担任其总裁、首席执行官和董事会成员。从1998年到2001年，他曾在ProDuct Health, Inc.（私有医疗设备公司）任职，并担任首席科学家（1998年到1999年）和总裁兼首席执行官（1999年到2001年）。从1996年到1998年,Hung在喀戎公司担任各种高级职位,包括领导发现和发展的副总裁和新项目的副总裁。从2001年12月到2001年1月，他担任Cytyc Health Corporation的顾问。获得的加州大学旧金山,医学院的医学博士学位,以及哈佛大学的生物学AB学位。是一个上市的生物制药公司（活跃于临床药物开发）的首席执行官。
David Hung has served as a Director since May 2006. Dr. Hung has served as the president, chief executive officer and as a director of Medivation, Inc. since December 2004. Dr. Hung also has served as the president and chief executive officer, and member of the board of directors, of Medivation, Inc.'s subsidiary, Medivation Neurology, Inc., since its inception in September 2003. From 1998 until 2001 Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer (1998-1999), and as president and chief executive officer (1999-2001). From December 2001 to January 2003 Dr. Hung served as a consultant to Cytyc Health Corporation. Dr. Hung received his M.D. from the University of California at San Francisco, and his A.B. in biology and organic chemistry from Harvard College. As the chief executive officer of a public biopharmaceutical company actively engaged in clinical drug development, Dr. Hung offers extensive experience in numerous aspects of managing a pre-commercialization drug development company, including strategic planning, clinical development, and strategic partnering. - David Hung，担任ARYA Sciences Acquisition Corp.的董事。Hung博士最近担任Axovant Biosciences Inc.的首席执行官(从2017年4月到2018年2月辞职)。2006年5月以来，他担任Acer Therapeutics Inc.董事。2004年12月以来，他担任Medivation, Inc.的总裁、首席执行官和董事。2003年9月Medivation, Inc.的子公司Medivation Neurology, Inc.成立以来，他担任其总裁、首席执行官和董事会成员。从1998年到2001年，他曾在ProDuct Health, Inc.（私有医疗设备公司）任职，并担任首席科学家（1998年到1999年）和总裁兼首席执行官（1999年到2001年）。从1996年到1998年,Hung在喀戎公司担任各种高级职位,包括领导发现和发展的副总裁和新项目的副总裁。从2001年12月到2001年1月，他担任Cytyc Health Corporation的顾问。获得的加州大学旧金山,医学院的医学博士学位,以及哈佛大学的生物学AB学位。是一个上市的生物制药公司（活跃于临床药物开发）的首席执行官。
- David Hung has served as a Director since May 2006. Dr. Hung has served as the president, chief executive officer and as a director of Medivation, Inc. since December 2004. Dr. Hung also has served as the president and chief executive officer, and member of the board of directors, of Medivation, Inc.'s subsidiary, Medivation Neurology, Inc., since its inception in September 2003. From 1998 until 2001 Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer (1998-1999), and as president and chief executive officer (1999-2001). From December 2001 to January 2003 Dr. Hung served as a consultant to Cytyc Health Corporation. Dr. Hung received his M.D. from the University of California at San Francisco, and his A.B. in biology and organic chemistry from Harvard College. As the chief executive officer of a public biopharmaceutical company actively engaged in clinical drug development, Dr. Hung offers extensive experience in numerous aspects of managing a pre-commercialization drug development company, including strategic planning, clinical development, and strategic partnering.
- Lisa N. Colleran
-
Lisa N. Colleran在2008年被任命为LifeCell Corporation的总裁。她之前是LifeCell商业运营的高级副总裁，负责销售和市场营销，外科医生教育，新产品发布和业务发展，以及领导公司的组织服务组织。自从2002年加入LifeCell以来，她担任营销和业务开发的副总裁以及商业运营的高级副总裁。加入LifeCell之前，她在Baxter Healthcare Corporation工作20年，担任各种销售，营销，业务开发和综合管理角色，责任增加，拥有国际经验。她在1997年被任命Baxter美国肾业务营销的副总裁，担任该角色直到2001年她被提升为公司肾制药业务的副总裁/总经理。
Lisa N. Colleran has served on our board of directors since November 2015. She served as Global President of LifeCell Corporation from August 2008 to January 2012 after the company was acquired by Kinetic Concepts, Inc. In January 2012 Ms. Colleran was appointed Chief Executive Officer and Director of LifeCell Corporation, a position she held until April 2013. Ms. Colleran originally joined LifeCell in 2002 as the Vice President of Marketing and Business Development and later served as Senior Vice President of Commercial Operations. Prior to joining LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare Corporation in various sales, marketing, business development and general management roles with international experience. She was appointed Vice President, Marketing for Baxter's U.S. Renal business in 1997 and served in that role until 2001 when she was promoted to Vice President/General Manager of the company's Renal Pharmaceuticals business. Ms. Colleran received her Bachelor of Science from Molloy College and an M.B.A. from Loyola University of Chicago. - Lisa N. Colleran在2008年被任命为LifeCell Corporation的总裁。她之前是LifeCell商业运营的高级副总裁，负责销售和市场营销，外科医生教育，新产品发布和业务发展，以及领导公司的组织服务组织。自从2002年加入LifeCell以来，她担任营销和业务开发的副总裁以及商业运营的高级副总裁。加入LifeCell之前，她在Baxter Healthcare Corporation工作20年，担任各种销售，营销，业务开发和综合管理角色，责任增加，拥有国际经验。她在1997年被任命Baxter美国肾业务营销的副总裁，担任该角色直到2001年她被提升为公司肾制药业务的副总裁/总经理。
- Lisa N. Colleran has served on our board of directors since November 2015. She served as Global President of LifeCell Corporation from August 2008 to January 2012 after the company was acquired by Kinetic Concepts, Inc. In January 2012 Ms. Colleran was appointed Chief Executive Officer and Director of LifeCell Corporation, a position she held until April 2013. Ms. Colleran originally joined LifeCell in 2002 as the Vice President of Marketing and Business Development and later served as Senior Vice President of Commercial Operations. Prior to joining LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare Corporation in various sales, marketing, business development and general management roles with international experience. She was appointed Vice President, Marketing for Baxter's U.S. Renal business in 1997 and served in that role until 2001 when she was promoted to Vice President/General Manager of the company's Renal Pharmaceuticals business. Ms. Colleran received her Bachelor of Science from Molloy College and an M.B.A. from Loyola University of Chicago.
高管简历
中英对照 | 中文 | 英文- Juan Jose Chacon Quiros
Juan Jose Chacon Quiros于2004年创立了Establishment Labs，S.A.，并自2013年成立以来一直担任Establishment Labs HoldingsInc.的董事兼首席执行官。Chacon Quiros先生一直参与美学行业的几个部门，包括担任拉丁美洲美容医疗器械分销业务的总经理近十年，在此之前，担任哥斯达黎加整形和重建外科诊所的业务开发经理。他也曾担任the Rugby Federation of Costa的总裁（从2009年到2015年）。Chac&243；n Quir&243；s先生在普瓦捷经济学院（Academie de Poitiers Economics）获得学士学位，并在马萨诸塞州阿默斯特大学（University of Massachusetts at Amherst）就读。他持有the MIT Sloan Advanced Certificate for Executives（ACE）的管理、创新和技术。
Juan Jose Chacon Quiros founded Establishment Labs, S.A. in 2004 and has been a director and the Chief Executive Officer of Establishment Labs Holdings Inc. since its inception in 2013. Mr. Chacon Quiros has been involved in several sectors of the aesthetics industry, including serving for almost a decade as General Manager of an aesthetic medical device distribution business in Latin America, and prior to that as Business Development Manager of a plastic and reconstructive surgery clinic in Costa Rica. He also served as President of the Rugby Federation of Costa Rica from 2009 to 2015. Mr. Chacón Quirós received his Baccalaureate at the Academie de Poitiers Economics and attended the University of Massachusetts at Amherst. He holds the MIT Sloan Advanced Certificate for Executives (ACE) in Management, Innovation and Technology.- Juan Jose Chacon Quiros于2004年创立了Establishment Labs，S.A.，并自2013年成立以来一直担任Establishment Labs HoldingsInc.的董事兼首席执行官。Chacon Quiros先生一直参与美学行业的几个部门，包括担任拉丁美洲美容医疗器械分销业务的总经理近十年，在此之前，担任哥斯达黎加整形和重建外科诊所的业务开发经理。他也曾担任the Rugby Federation of Costa的总裁（从2009年到2015年）。Chac&243；n Quir&243；s先生在普瓦捷经济学院（Academie de Poitiers Economics）获得学士学位，并在马萨诸塞州阿默斯特大学（University of Massachusetts at Amherst）就读。他持有the MIT Sloan Advanced Certificate for Executives（ACE）的管理、创新和技术。
- Juan Jose Chacon Quiros founded Establishment Labs, S.A. in 2004 and has been a director and the Chief Executive Officer of Establishment Labs Holdings Inc. since its inception in 2013. Mr. Chacon Quiros has been involved in several sectors of the aesthetics industry, including serving for almost a decade as General Manager of an aesthetic medical device distribution business in Latin America, and prior to that as Business Development Manager of a plastic and reconstructive surgery clinic in Costa Rica. He also served as President of the Rugby Federation of Costa Rica from 2009 to 2015. Mr. Chacón Quirós received his Baccalaureate at the Academie de Poitiers Economics and attended the University of Massachusetts at Amherst. He holds the MIT Sloan Advanced Certificate for Executives (ACE) in Management, Innovation and Technology.
- Salvador Dada Santos
Salvador Dada Santos于2016年2月被任命为我们的首席运营官，并自2009年4月起担任运营和制造经理。Dada从2007年到2009年在Allergan Medical担任多个工程职位，从2004年到2006年在Establishment Biotech，S.A.担任多个生产和制造职位。Dada先生在哥斯达黎加大学（University of Costa Rica）获得工业工程本科和执照学位。
Salvador Dada Santos was appointed as our Chief Operating Officer in February 2016 and has served as a manager of operations and manufacturing since April 2009. Mr. Dada served in various engineering roles at Allergan Medical from 2007 to 2009 and in various production and manufacturing roles at Establishment Biotech, S.A. from 2004 to 2006. Mr. Dada received undergraduate and licentiate degrees in Industrial Engineering from the University of Costa Rica.- Salvador Dada Santos于2016年2月被任命为我们的首席运营官，并自2009年4月起担任运营和制造经理。Dada从2007年到2009年在Allergan Medical担任多个工程职位，从2004年到2006年在Establishment Biotech，S.A.担任多个生产和制造职位。Dada先生在哥斯达黎加大学（University of Costa Rica）获得工业工程本科和执照学位。
- Salvador Dada Santos was appointed as our Chief Operating Officer in February 2016 and has served as a manager of operations and manufacturing since April 2009. Mr. Dada served in various engineering roles at Allergan Medical from 2007 to 2009 and in various production and manufacturing roles at Establishment Biotech, S.A. from 2004 to 2006. Mr. Dada received undergraduate and licentiate degrees in Industrial Engineering from the University of Costa Rica.
- Roberto De Mezerville
Roberto De Mezerville于2018年2月被任命为我们的首席技术官，自2009年以来，他在我们公司的质量管理、研究与开发、监管和临床事务等领域担任着越来越重要的职务，并于2015年6月至2018年2月担任我们的质量和研发Vice President。De Mezerville从2006年到2009年在Allergan Medical Costa担任多个工程和质量管理职位。他持有Universidad Interamericana de Costa的工商管理学士学位，以及Instituto Tecnologico de Costa的工业环境健康和安全工程学士学位。
Roberto De Mezerville was appointed as our Chief Technology Officer in February 2018 and has held positions of increasing responsibility at our company since 2009 in the areas of quality management, research and development, regulatory and clinical affairs, and was our Vice President of Quality and R&D from June 2015 to February 2018. From 2006 to 2009 Mr. De Mezerville served in various engineering and quality management positions with Allergan Medical Costa Rica. He has a Bachelor’s Degree in Business Administration from Universidad Interamericana de Costa Rica and a Bachelor’s degree in Industrial Environmental Health and Safety Engineering from Instituto Tecnologico de Costa Rica.- Roberto De Mezerville于2018年2月被任命为我们的首席技术官，自2009年以来，他在我们公司的质量管理、研究与开发、监管和临床事务等领域担任着越来越重要的职务，并于2015年6月至2018年2月担任我们的质量和研发Vice President。De Mezerville从2006年到2009年在Allergan Medical Costa担任多个工程和质量管理职位。他持有Universidad Interamericana de Costa的工商管理学士学位，以及Instituto Tecnologico de Costa的工业环境健康和安全工程学士学位。
- Roberto De Mezerville was appointed as our Chief Technology Officer in February 2018 and has held positions of increasing responsibility at our company since 2009 in the areas of quality management, research and development, regulatory and clinical affairs, and was our Vice President of Quality and R&D from June 2015 to February 2018. From 2006 to 2009 Mr. De Mezerville served in various engineering and quality management positions with Allergan Medical Costa Rica. He has a Bachelor’s Degree in Business Administration from Universidad Interamericana de Costa Rica and a Bachelor’s degree in Industrial Environmental Health and Safety Engineering from Instituto Tecnologico de Costa Rica.
- Jeremy Livianu
Jeremy Livianu自2018年4月起担任我们的总法律顾问。2014年2月至2018年3月，Livianu先生担任加利福尼亚州雷德伍德市医疗设备公司NevroCorp.的全球法律事务总监兼梦百合合规和隐私官。2010年3月至2014年2月，Livianu先生支持强生公司生命科学公司的梦百合合规全球外科集团。Livianu先生还曾担任Tethys Bioscience的公司法律顾问，并在O’；Melveny&Myers LLP和Paul，Hastings，Janofsky，&Walker LLP从事知识产权法执业。Livianu先生在乔治华盛顿大学法学院（George Washington University Law School）以优异成绩获得法学博士学位，并在加州大学圣地亚哥分校（University of California，San Diego）获得化学工程理学士学位。
Jeremy Livianu has been our General Counsel since April 2018. From February 2014 to March 2018 Mr. Livianu was the Global Director of Legal Affairs and Healthcare Compliance and Privacy Officer at Nevro Corp., a medical device company in Redwood City, California. From March 2010 to February 2014 Mr. Livianu supported Johnson & Johnson life science companies in their healthcare compliance Global Surgery Group. Mr. Livianu also served as Corporate Counsel for Tethys Bioscience and practiced intellectual property law at O’Melveny & Myers LLP and Paul, Hastings, Janofsky, & Walker LLP. Mr. Livianu received his J.D. with honors from The George Washington University Law School and his Bachelor of Science in Chemical Engineering from the University of California, San Diego.- Jeremy Livianu自2018年4月起担任我们的总法律顾问。2014年2月至2018年3月，Livianu先生担任加利福尼亚州雷德伍德市医疗设备公司NevroCorp.的全球法律事务总监兼梦百合合规和隐私官。2010年3月至2014年2月，Livianu先生支持强生公司生命科学公司的梦百合合规全球外科集团。Livianu先生还曾担任Tethys Bioscience的公司法律顾问，并在O’；Melveny&Myers LLP和Paul，Hastings，Janofsky，&Walker LLP从事知识产权法执业。Livianu先生在乔治华盛顿大学法学院（George Washington University Law School）以优异成绩获得法学博士学位，并在加州大学圣地亚哥分校（University of California，San Diego）获得化学工程理学士学位。
- Jeremy Livianu has been our General Counsel since April 2018. From February 2014 to March 2018 Mr. Livianu was the Global Director of Legal Affairs and Healthcare Compliance and Privacy Officer at Nevro Corp., a medical device company in Redwood City, California. From March 2010 to February 2014 Mr. Livianu supported Johnson & Johnson life science companies in their healthcare compliance Global Surgery Group. Mr. Livianu also served as Corporate Counsel for Tethys Bioscience and practiced intellectual property law at O’Melveny & Myers LLP and Paul, Hastings, Janofsky, & Walker LLP. Mr. Livianu received his J.D. with honors from The George Washington University Law School and his Bachelor of Science in Chemical Engineering from the University of California, San Diego.
- Alberto Quesada
Alberto Quesada于2017年1月加入我们，担任我们的质量和OU法规事务Vice President。Quesada从2010年5月到2016年12月担任哥斯达黎加Boston Scientific质量总监和管理代表，2010年5月至2016年6月，他曾担任公司位于赫雷迪亚的网站的质量总监，随后于2016年7月至2016年12月担任公司位于科约尔的网站的管理代表。此前，他曾任职Allergan Corporation（2000年11月至2010年5月），在那里他曾担任高级质量管理职务。他还曾在Baxter梦百合Corporation、Kativo Chemical Industries和GTE Sylvania担任职务。Quesada先生在哥斯达黎加的Universidad Estatal A Distancia UNED获得工商管理硕士学位，并在哥斯达黎加大学（University of Costa Rica）获得工业工程本科学位。
Alberto Quesada joined us in January 2017 as our Vice President of Quality and OUS Regulatory Affairs. From May 2010 to December 2016 Mr. Quesada was a Quality Director and Management Representative at Boston Scientific in Costa Rica, where he was a Quality Director at the company’s site in Heredia from May 2010 to June 2016 and then a Management Representative at the company’s site in Coyol from July 2016 to December 2016. Prior to that, Mr. Quesada was with Allergan Corporation from November 2000 to May 2010 where he served in senior quality management roles. He also previously held roles at Baxter Healthcare Corporation, Kativo Chemical Industries and GTE Sylvania. Mr. Quesada received his M.B.A. from Universidad Estatal a Distancia UNED, Costa Rica and his undergraduate degree in Industrial Engineering from the University of Costa Rica.- Alberto Quesada于2017年1月加入我们，担任我们的质量和OU法规事务Vice President。Quesada从2010年5月到2016年12月担任哥斯达黎加Boston Scientific质量总监和管理代表，2010年5月至2016年6月，他曾担任公司位于赫雷迪亚的网站的质量总监，随后于2016年7月至2016年12月担任公司位于科约尔的网站的管理代表。此前，他曾任职Allergan Corporation（2000年11月至2010年5月），在那里他曾担任高级质量管理职务。他还曾在Baxter梦百合Corporation、Kativo Chemical Industries和GTE Sylvania担任职务。Quesada先生在哥斯达黎加的Universidad Estatal A Distancia UNED获得工商管理硕士学位，并在哥斯达黎加大学（University of Costa Rica）获得工业工程本科学位。
- Alberto Quesada joined us in January 2017 as our Vice President of Quality and OUS Regulatory Affairs. From May 2010 to December 2016 Mr. Quesada was a Quality Director and Management Representative at Boston Scientific in Costa Rica, where he was a Quality Director at the company’s site in Heredia from May 2010 to June 2016 and then a Management Representative at the company’s site in Coyol from July 2016 to December 2016. Prior to that, Mr. Quesada was with Allergan Corporation from November 2000 to May 2010 where he served in senior quality management roles. He also previously held roles at Baxter Healthcare Corporation, Kativo Chemical Industries and GTE Sylvania. Mr. Quesada received his M.B.A. from Universidad Estatal a Distancia UNED, Costa Rica and his undergraduate degree in Industrial Engineering from the University of Costa Rica.
- Eddie De Oliveira
自2016年2月以来，Eddie De Oliveira一直是我们在巴西的销售Vice President。2012年1月至2016年1月，de Oliveira先生担任巴西Gc Aesthetics Plc执行国家主任。在此之前，de Oliveira先生参与了GC Aesthetics&8217；在法国和西班牙的子公司的设立，并于2008年至2012年和2010年至2012年分别担任GC Aesthetics&8217；子公司EuroSilicon和Nagor的国际营销经理。de Oliveira先生在AIX-Marseille Graduate School of Management France获得工商管理硕士学位。
Eddie De Oliveira has been our Vice President of Sales for Brazil since February 2016. From January 2012 to January 2016 Mr. De Oliveira was the Executive Country Director in Brazil for GC Aesthetics plc. Prior to that, Mr. De Oliveira was involved in the setup of the GC Aesthetics’ subsidiaries in France and Spain and served as Manager for International Marketing for GC Aesthetics’ subsidiaries Eurosilicone from 2008 to 2012 and Nagor from 2010 to 2012. Mr. De Oliveira received an M.B.A. from the Aix-Marseille Graduate School of Management France.- 自2016年2月以来，Eddie De Oliveira一直是我们在巴西的销售Vice President。2012年1月至2016年1月，de Oliveira先生担任巴西Gc Aesthetics Plc执行国家主任。在此之前，de Oliveira先生参与了GC Aesthetics&8217；在法国和西班牙的子公司的设立，并于2008年至2012年和2010年至2012年分别担任GC Aesthetics&8217；子公司EuroSilicon和Nagor的国际营销经理。de Oliveira先生在AIX-Marseille Graduate School of Management France获得工商管理硕士学位。
- Eddie De Oliveira has been our Vice President of Sales for Brazil since February 2016. From January 2012 to January 2016 Mr. De Oliveira was the Executive Country Director in Brazil for GC Aesthetics plc. Prior to that, Mr. De Oliveira was involved in the setup of the GC Aesthetics’ subsidiaries in France and Spain and served as Manager for International Marketing for GC Aesthetics’ subsidiaries Eurosilicone from 2008 to 2012 and Nagor from 2010 to 2012. Mr. De Oliveira received an M.B.A. from the Aix-Marseille Graduate School of Management France.
- Renee Gaeta
Renee Gaeta，自2022年8月起担任Candel董事会成员。Gaeta女士目前是Eko Devices，Inc.的首席财务官，Eko Devices，Inc.是一家专注于心肺数字健康解决方案的私营公司，自2021年7月起担任该职位。在此之前的2017年7月至2021年7月，Gaeta女士是Establishment Labs控股公司的首席财务官，该公司是一家上市的全球性医疗设备公司，专注于美容技术。2014年8月至2017年6月，Gaeta女士担任Sientra, Inc.副总裁兼公司财务总监，该公司是一家上市的全球医疗美容公司，她是该公司执行团队的成员，并领导财务部门。2004年至2014年，加埃塔在毕马威、LLP或毕马威工作。Gaeta女士曾在毕马威担任多个职位，最近担任交易和重组小组的咨询主任。Gaeta女士还担任SeaSpine控股公司董事，直至2023年1月（纳斯达克：SPNE），从2019年2月至2023年1月，该公司被Orthofix Medical Inc.（纳斯达克：OFIX）收购。Gaeta女士以优异成绩获得了洛约拉玛丽蒙特大学会计学学士学位，是加利福尼亚州的注册会计师。
Renee Gaeta,has served as a member of Candel's board of directors since August 2022. Ms. Gaeta currently is Chief Financial Officer of Eko Devices, Inc., a private company focused on cardiopulmonary digital health solutions, a position she has held since July 2021. Prior to that, from July 2017 to July 2021, Ms. Gaeta was Chief Financial Officer at Establishment Labs Holdings, Inc., a publicly traded global medical device company focused on aesthetic technologies. From August 2014 to June 2017, Ms. Gaeta was Vice President and Corporate Controller at Sientra, Inc., a publicly traded global medical aesthetics company, where she was a member of the executive team and headed the finance department. From 2004 to 2014, Ms. Gaeta worked at KPMG, LLP, or KPMG. Ms. Gaeta held various positions at KPMG, most recently as an Advisory Director in the Transactions and Restructuring Group. Ms. Gaeta also served as a director of SeaSpine Holdings Corp until January 2023 (Nasdaq: SPNE) from February 2019 until January 2023, when it was acquired by Orthofix Medical Inc. (Nasdaq: OFIX). Ms. Gaeta received her B.S., cum laude, in Accounting from Loyola Marymount University and is a Certified Public Accountant in the State of California.- Renee Gaeta，自2022年8月起担任Candel董事会成员。Gaeta女士目前是Eko Devices，Inc.的首席财务官，Eko Devices，Inc.是一家专注于心肺数字健康解决方案的私营公司，自2021年7月起担任该职位。在此之前的2017年7月至2021年7月，Gaeta女士是Establishment Labs控股公司的首席财务官，该公司是一家上市的全球性医疗设备公司，专注于美容技术。2014年8月至2017年6月，Gaeta女士担任Sientra, Inc.副总裁兼公司财务总监，该公司是一家上市的全球医疗美容公司，她是该公司执行团队的成员，并领导财务部门。2004年至2014年，加埃塔在毕马威、LLP或毕马威工作。Gaeta女士曾在毕马威担任多个职位，最近担任交易和重组小组的咨询主任。Gaeta女士还担任SeaSpine控股公司董事，直至2023年1月（纳斯达克：SPNE），从2019年2月至2023年1月，该公司被Orthofix Medical Inc.（纳斯达克：OFIX）收购。Gaeta女士以优异成绩获得了洛约拉玛丽蒙特大学会计学学士学位，是加利福尼亚州的注册会计师。
- Renee Gaeta,has served as a member of Candel's board of directors since August 2022. Ms. Gaeta currently is Chief Financial Officer of Eko Devices, Inc., a private company focused on cardiopulmonary digital health solutions, a position she has held since July 2021. Prior to that, from July 2017 to July 2021, Ms. Gaeta was Chief Financial Officer at Establishment Labs Holdings, Inc., a publicly traded global medical device company focused on aesthetic technologies. From August 2014 to June 2017, Ms. Gaeta was Vice President and Corporate Controller at Sientra, Inc., a publicly traded global medical aesthetics company, where she was a member of the executive team and headed the finance department. From 2004 to 2014, Ms. Gaeta worked at KPMG, LLP, or KPMG. Ms. Gaeta held various positions at KPMG, most recently as an Advisory Director in the Transactions and Restructuring Group. Ms. Gaeta also served as a director of SeaSpine Holdings Corp until January 2023 (Nasdaq: SPNE) from February 2019 until January 2023, when it was acquired by Orthofix Medical Inc. (Nasdaq: OFIX). Ms. Gaeta received her B.S., cum laude, in Accounting from Loyola Marymount University and is a Certified Public Accountant in the State of California.